Capricor Therapeutics Inc (CAPR) Upgraded to “Hold” at Zacks Investment Research

Zacks Investment Research upgraded shares of Capricor Therapeutics Inc (OTCMKTS:CAPR) from a sell rating to a hold rating in a report published on Thursday.

According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “

A number of other research firms have also recently weighed in on CAPR. HC Wainwright assumed coverage on shares of Capricor Therapeutics in a research report on Wednesday, July 6th. They set a buy rating and a $13.00 price objective for the company. Roth Capital assumed coverage on shares of Capricor Therapeutics in a research report on Wednesday, June 15th. They set a buy rating and a $12.00 price objective for the company.

Shares of Capricor Therapeutics (OTCMKTS:CAPR) opened at 3.63 on Thursday. Capricor Therapeutics has a one year low of $1.88 and a one year high of $5.40. The firm has a 50-day moving average of $3.69 and a 200-day moving average of $3.51. The company’s market capitalization is $65.17 million.

Capricor Therapeutics (OTCMKTS:CAPR) last released its quarterly earnings data on Monday, August 15th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. Analysts forecast that Capricor Therapeutics will post ($1.04) earnings per share for the current year.

In other Capricor Therapeutics news, major shareholder Sinai Medical Center Cedars bought 312,500 shares of Capricor Therapeutics stock in a transaction dated Wednesday, September 21st. The stock was acquired at an average cost of $3.20 per share, for a total transaction of $1,000,000.00. Following the completion of the transaction, the insider now directly owns 2,904,798 shares of the company’s stock, valued at $9,295,353.60. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

A hedge fund recently raised its stake in Capricor Therapeutics stock. Vanguard Group Inc. boosted its stake in Capricor Therapeutics Inc (OTCMKTS:CAPR) by 25.6% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 27,975 shares of the company’s stock after buying an additional 5,704 shares during the period. Vanguard Group Inc. owned 0.16% of Capricor Therapeutics worth $111,000 as of its most recent SEC filing.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications.

Receive News & Ratings for Capricor Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics Inc and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.